<DOC>
	<DOCNO>NCT02553798</DOCNO>
	<brief_summary>This open-label , long-term safety study DRM04 Topical Wipes , enrol 660 subject primary axillary hyperhidrosis participate either DRM04-HH04 DRM04-HH05 study .</brief_summary>
	<brief_title>Long-term Safety Study DRM04 Subjects With Primary Axillary Hyperhidrosis</brief_title>
	<detailed_description>Safety assess adverse event , blood urine laboratory test , physical examination , pulse blood pressure . Local skin reaction assess include burning/stinging , pruritus , edema , erythema , dryness scaling .</detailed_description>
	<mesh_term>Hyperhidrosis</mesh_term>
	<criteria>Completed Day 28 either DRM04HH04 DRM04HH05 study least 80 % treatment compliance Male female Subject clinically significant abnormality physical exam , vital sign ECG Week 4 visit DRM04HH04 DRM04HH05 study would make treatment DRM04 contraindicate Male history urinary retention require catheterization due prostatic hypertrophy severe obstructive symptom prostatic hypertrophy Any condition , judgement Investigator , would put subject unacceptable risk participation study</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>